129 related articles for article (PubMed ID: 7682753)
21. [Concentration of annexin V in gestational tissues: placenta, fetal membranes, myometrium and amniotic fluid].
Uszyński W; Zekanowska E; Uszyński M; Rystok D
Ginekol Pol; 2006 Aug; 77(8):603-9. PubMed ID: 17076191
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Koh SC; Anandakumar C; Montan S; Ratnam SS
Gynecol Obstet Invest; 1993; 35(4):214-21. PubMed ID: 8330765
[TBL] [Abstract][Full Text] [Related]
23. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
Nilsson IM; Ljungnér H; Tengborn L
Br Med J (Clin Res Ed); 1985 May; 290(6480):1453-6. PubMed ID: 3922531
[TBL] [Abstract][Full Text] [Related]
24. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes.
Vadillo-Ortega F; Hernandez A; Gonzalez-Avila G; Bermejo L; Iwata K; Strauss JF
Am J Obstet Gynecol; 1996 Apr; 174(4):1371-6. PubMed ID: 8623872
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
Vesce F; Scapoli C; Giovannini G; Piffanelli A; Geurts-Moespot A; Sweep FC
Obstet Gynecol; 2001 Mar; 97(3):404-8. PubMed ID: 11239646
[TBL] [Abstract][Full Text] [Related]
27. [Fibrinolytic system of the skin: localization and modulation of plasminogen activator (PA) and PA inhibitor].
Izaki S; Hibino T
Rinsho Ketsueki; 1987 Jul; 28(7):1127-33. PubMed ID: 3121894
[No Abstract] [Full Text] [Related]
28. Matrix metalloproteinase 3 in parturition, premature rupture of the membranes, and microbial invasion of the amniotic cavity.
Park KH; Chaiworapongsa T; Kim YM; Espinoza J; Yoshimatsu J; Edwin S; Gomez R; Yoon BH; Romero R
J Perinat Med; 2003; 31(1):12-22. PubMed ID: 12661139
[TBL] [Abstract][Full Text] [Related]
29. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ
Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427
[TBL] [Abstract][Full Text] [Related]
30. Pregnancy-induced changes in the fibrinolytic balance: evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor.
Gore M; Eldon S; Trofatter KF; Soong SJ; Pizzo SV
Am J Obstet Gynecol; 1987 Mar; 156(3):674-80. PubMed ID: 3493696
[TBL] [Abstract][Full Text] [Related]
31. [Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report].
Shiba E; Kobayashi T; Yayoi E; Takatsuka Y; Koyama H; Takai S; Mori T
Nihon Geka Gakkai Zasshi; 1992 Jan; 93(1):109. PubMed ID: 1549093
[No Abstract] [Full Text] [Related]
32. Involvement of fibrinolytic factors in mid trimester amniotic fluid with development of severe early-onset preeclampsia.
Adachi T; Nakabayashi M; Sakura M; Ando K
Semin Thromb Hemost; 1999; 25(5):447-50. PubMed ID: 10625200
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue.
Virtanen OJ; Sirén V; Multanen J; Färkkilä M; Leivo I; Vaheri A; Koskiniemi M
Eur J Oral Sci; 2006 Feb; 114(1):22-6. PubMed ID: 16460337
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Estellés A; Gilabert J; España F; Aznar J; Galbis M
Am J Obstet Gynecol; 1991 Jul; 165(1):138-42. PubMed ID: 1906680
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
Aznar J; Estellés A; Tormo G; Sapena P; Tormo V; Blanch S; España F
Br Heart J; 1988 May; 59(5):535-41. PubMed ID: 3132963
[TBL] [Abstract][Full Text] [Related]
36. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood.
Lecander I; Astedt B
J Lab Clin Med; 1987 Nov; 110(5):602-5. PubMed ID: 3499478
[TBL] [Abstract][Full Text] [Related]
37. Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid.
Verkleij-Hagoort AC; Ursem NT; Hop WC; Geurts-Moespot A; Steegers EA; Sweep FC; Steegers-Theunissen RP
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):47-52. PubMed ID: 17141398
[TBL] [Abstract][Full Text] [Related]
38. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
39. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
[TBL] [Abstract][Full Text] [Related]
40. [Choline content of normal, mature human fetal membrane, umbilical cord and amniotic fluid].
MISCHEL W
Zentralbl Gynakol; 1960 Jul; 82():1169-77. PubMed ID: 13771262
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
